These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 1280537

  • 1. Phase II study of cisplatin as a 5-day continuous infusion with vindesine plus recombinant human granulocyte-colony-stimulating factor in the treatment of advanced non-small-cell lung cancer.
    Saito Y, Mori K, Tominaga K, Yokoi K, Miyazawa N.
    Cancer Chemother Pharmacol; 1992; 31(2):81-4. PubMed ID: 1280537
    [Abstract] [Full Text] [Related]

  • 2. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
    Vokes EE, Haraf DJ, Drinkard LC, Hoffman PC, Ferguson MK, Vogelzang NJ, Watson S, Lane NJ, Golomb HM.
    Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
    [Abstract] [Full Text] [Related]

  • 3. Induction chemotherapy with and without recombinant human granulocyte colony-stimulating factor support in locally advanced stage IIIA/B non-small cell lung cancer.
    Fischer JR, Manegold C, Bülzebruck H, Vogt-Moykopf I, Drings P.
    Semin Oncol; 1994 Jun; 21(3 Suppl 4):20-7. PubMed ID: 7516094
    [Abstract] [Full Text] [Related]

  • 4. Mitomycin, cisplatin, and vindesine followed by radiotherapy combined with cisplatin in stage III nonsmall cell lung cancer: long-term results.
    Tejedor M, Valerdi JJ, López R, Domínguez MA, Arias F, Illarramendi JJ, Martínez E.
    Int J Radiat Oncol Biol Phys; 1995 Feb 15; 31(4):813-8. PubMed ID: 7860393
    [Abstract] [Full Text] [Related]

  • 5. Phase II trial of dose intensification with cisplatin and carboplatin plus vindesine in patients with inoperable non-small cell lung cancer.
    Nakanishi Y, Takayama K, Kawasaki M, Yatsunami J, Inutsuka S, Wakamatsu K, Tsuruta N, Hara N.
    Am J Clin Oncol; 1997 Aug 15; 20(4):393-7. PubMed ID: 9256897
    [Abstract] [Full Text] [Related]

  • 6. The use of granulocyte colony-stimulating factor to shorten the interval between cycles of mitomycin C, vindesine, and cisplatin chemotherapy in non-small-cell lung cancer.
    Takada M, Fukuoka M, Ariyoshi Y, Furuse K, Niitani H, Ota K, Motomiya M, Hasegawa K, Tominaga K, Kuriyama T.
    Cancer Chemother Pharmacol; 1992 Aug 15; 31(3):182-6. PubMed ID: 1281446
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
    Recchia F, Sica G, De Filippis S, Rosselli M, Saggio G, Guerriero G, Pompili P, Rea S.
    Anticancer Res; 2000 Aug 15; 20(3B):1985-90. PubMed ID: 10928138
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with lung cancer].
    Ohnoshi T, Ueoka H, Kodani T, Kamei H, Kimura I.
    Gan To Kagaku Ryoho; 1990 Apr 15; 17(4 Pt 2):911-8. PubMed ID: 1693062
    [Abstract] [Full Text] [Related]

  • 12. A study of dose escalation of teniposide (VM-26) plus cisplatin (CDDP) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with advanced small cell lung cancer.
    Eguchi K, Etou H, Miyachi S, Morinari H, Nakada K, Noda K, Ohkuni Y, Watanabe K, Yamada Y, Ohe Y.
    Eur J Cancer; 1994 Apr 15; 30A(2):188-94. PubMed ID: 7512356
    [Abstract] [Full Text] [Related]

  • 13. Alternating radiotherapy and chemotherapy for inoperable Stage III non-small-cell lung cancer: long-term results of two Phase II GOTHA trials. Groupe d'Oncologie Thoracique Alpine.
    Mirimanoff RO, Moro D, Bolla M, Michel G, Brambilla C, Mermillod B, Miralbell R, Alberto P.
    Int J Radiat Oncol Biol Phys; 1998 Oct 01; 42(3):487-94. PubMed ID: 9806505
    [Abstract] [Full Text] [Related]

  • 14. Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: results of a phase II Southwest Oncology Group study.
    Hazuka MB, Crowley JJ, Bunn PA, O'Rourke M, Braun TJ, Livingston RB.
    J Clin Oncol; 1994 Sep 01; 12(9):1814-20. PubMed ID: 8083705
    [Abstract] [Full Text] [Related]

  • 15. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
    Segawa Y, Ueoka H, Kiura K, Kamei H, Tabata M, Sakae K, Hiraki Y, Kawahara S, Eguchi K, Hiraki S, Harada M.
    Br J Cancer; 2000 Jan 01; 82(1):104-11. PubMed ID: 10638975
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Sequential treatment with vindesine-ifosfamide-platinum (VIP) chemotherapy followed by platinum sensitized radiotherapy in stage IIIB non-small cell lung cancer: a phase II trial.
    Van den Brande P, De Ruysscher D, Vansteenkiste J, Spaas P, Specenier P, Demedts M.
    Lung Cancer; 1998 Oct 01; 22(1):45-53. PubMed ID: 9869107
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
    Shinkai T, Arioka H, Kunikane H, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Oshita F, Nishio M, Karato A.
    Cancer Res; 1994 May 15; 54(10):2636-42. PubMed ID: 8168091
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.